TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV D1, D8, D15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV D1, D8, D15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1000mg/m2 IV or PO D1-5 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1000mg/m2 IV or PO D1-5 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375mg/m2 IV D1, D15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV D1, D15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100mg/m2 IV D15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg PO D1-21 every 28 days
Study: NCT05508451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double jaw surgery
Description: A type of orthognathic surgery
Study: NCT04123041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
Description: JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
Description: JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
Description: JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum
Description: JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
Study: NCT00002806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT04351256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Injection [Imfinzi]
Description: Durvalumab fixed dose of 1,500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab Injection [Imfinzi]
Description: Durvalumab fixed dose of 1,500 mg

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Radiotherapy (TRT) conventionally
Description: Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy (TRT) hypofractionated
Description: Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
Study: NCT02129244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCM-Plus
Description: The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients
Study: NCT04156581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a corticosteroid that reduces inflammation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is a mixture of NaCl and water that can be used as a placebo.
Study: NCT00657618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Stibogluconate (SSG)
Description: 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
Study: NCT03704376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml of 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 ml of 0.2% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mcg clonidine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency linear ultrasound transducer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency linear ultrasound transducer
Study: NCT01865370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang Pills
Description: Kochujang Pills (34.5g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (34.5g/day)
Study: NCT01445938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR97276A
Description: Pharmaceutical form:solution for injection~Route of administration: intramuscular

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter + lumefantrine (ACTs)
Description: Pharmaceutical form:tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arthemeter + lumefantrine (ACTs)
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01405950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.025 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.05 mg/kg
Study: NCT04680455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online home-based strength training
Description: Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
Study: NCT00489970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taking of blood samples
Description: No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taking of blood samples
Description: No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adacel
Description: A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
Study: NCT03870750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Palliative Care
Description: focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Palliative Care
Description: focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Management
Description: physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Management
Description: physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study: NCT04334668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Chloride
Description: Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
Study: NCT03320070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel for SC injection
Study: NCT02358603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chronotropic Incompetence Diagnostic Algorithm

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Chronotropic Incompetence Diagnostic Algorithm
Study: NCT05166408

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Buccinator myomucosal flap
Description: Buccinator myomucosal flap for primary cleft palate palatoplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bardach two flap palatoplasty
Description: Bardach two flap palatoplasty
Study: NCT01205594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
Study: NCT01912612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
Study: NCT01089426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven™
Description: 1 g/kg/d of Omegaven until discontinuation of PN
Study: NCT02646644

Intervention type: OTHER
Intervention: Metastasized intestinal NET
Description: This is an observational study
Study: NCT00659971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAC113
Description: PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
Study: NCT00347958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Description: 0.5mL, Intramuscular (IM)
Study: NCT03688867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation regimen
Description: The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log.
Study: NCT01569971

Intervention type: OTHER
Intervention: Assessment
Description: In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.

Intervention type: OTHER
Intervention: Assessment
Description: In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.

Intervention type: OTHER
Intervention: Assessment
Description: In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Study: NCT02476578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Email
Description: Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
Study: NCT00786760

Intervention type: OTHER
Intervention: Cohort: 3000 men examined every 6 months for 4 years.
Description: Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
Study: NCT01089426

Intervention type: OTHER
Group type: OTHER
Intervention: Historical Controls
Description: Standard of Care
Study: NCT01921569

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Therapy
Description: Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Therapy
Description: Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM Injection
Description: Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: Injection into affected area with 1.0 cc normal saline solution instead of active agent.
Study: NCT03009045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid
Description: 200mg oral tedizolid one pill per day
Study: NCT02434692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARGOS-IO system
Description: Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
Study: NCT00786760

Intervention type: OTHER
Intervention: Pilot study: 150 men examined every 6 months for 4 years.
Description: Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
Study: NCT01065337

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tissue repair cells (TRC)
Description: expanded bone marrow cells enriched in CD90+ mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tissue repair cells (TRC)
Description: expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
Study: NCT00778648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus
Description: Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four capsules of placebo daily.
Study: NCT03695172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
Study: NCT04310800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT-plug technique
Description: Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT-plug technique
Description: Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
Study: NCT00908245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Surgery without preconditioning surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preconditioning ischemia
Description: Surgery with a preconditioning ischemia
Study: NCT01405950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.075 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanaflex Capsules
Description: 0.1 mg/kg